PDCD1 and cancer: One notable milestone in the immunotherapy of cancer, in general, as well as for ovarian cancer, in particular, was touched on when studies on the programmed cell death receptor 1 (PD-1) and its ligands programmed death-ligand 1 and 2 (PD-L1/PD-L2) interactions were revealed [19].